Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor Immunosuppression

Cantargia AB ( (SE:CANTA) ) just unveiled an update.

Cantargia AB has published preclinical data in Cancer Discovery, showcasing the potential of nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. The findings indicate that blocking IL1RAP can overcome resistance to immune therapy, with clinical data supporting the reduction of immunosuppressive cells and improved outcomes in cancer treatment. This development could enhance Cantargia’s positioning in the oncology sector by offering a promising approach to improving immunotherapy outcomes, potentially benefiting stakeholders and patients alike.

More about Cantargia AB

Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. It has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. The company’s primary oncology program involves the antibody nadunolimab (CAN04), studied mainly in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia also has a second development program, CAN10, targeting serious autoimmune/inflammatory diseases.

YTD Price Performance: -2.61%

Average Trading Volume: 2,500

Technical Sentiment Signal: Buy

Current Market Cap: €36.77M

For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.